CN Patent

CN112263577B — 罗氟司特晶体生长的抑制

Assigned to Alcutis Biotherapy Co ltd · Expires 2024-07-09 · 2y expired

What this patent protects

本发明涉及罗氟司特晶体生长的抑制。具体而言，本发明涉及包含罗氟司特和己二醇的组合物在制备用于抑制患者中的磷酸二酯酶4的药物中的用途，其中所述药物用于将所述包含罗氟司特和己二醇的组合物每天1‑2次给药至有此需要的所述患者，其中所述己二醇以0.1‑20％w/w的量加入，且所述己二醇为2‑甲基‑2,4‑戊二醇。

USPTO Abstract

本发明涉及罗氟司特晶体生长的抑制。具体而言，本发明涉及包含罗氟司特和己二醇的组合物在制备用于抑制患者中的磷酸二酯酶4的药物中的用途，其中所述药物用于将所述包含罗氟司特和己二醇的组合物每天1‑2次给药至有此需要的所述患者，其中所述己二醇以0.1‑20％w/w的量加入，且所述己二醇为2‑甲基‑2,4‑戊二醇。

Drugs covered by this patent

Patent Metadata

Patent number
CN112263577B
Jurisdiction
CN
Classification
—
Expires
2024-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Alcutis Biotherapy Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.